Cambridge, MA, United States of America

Steve Bottega

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 12.4

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2013-2023

Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: Innovations of Steve Bottega

Introduction

Steve Bottega is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 8 patents to his name, Bottega's work has the potential to impact the treatment of various cell proliferative diseases, including cancer.

Latest Patents

Among his latest patents are the Anti-ErbB3 antibodies. These monoclonal antibodies are designed to bind and inhibit the activation of the epidermal growth factor receptor-related member ErbB3/HER3. The therapeutic applications of these antibodies are particularly relevant for treating certain forms of cancer associated with the activation of ErbB3/HER3.

Career Highlights

Steve Bottega is currently associated with Aveo Pharmaceuticals, Inc., where he continues to innovate in the field of cancer treatment. His expertise in monoclonal antibody development has positioned him as a key figure in the biotechnology sector.

Collaborations

Some of his notable coworkers include Sylvie Vincent and Kristan Meetze, who contribute to the collaborative efforts in research and development at Aveo Pharmaceuticals.

Conclusion

Steve Bottega's work in developing Anti-ErbB3 antibodies showcases his commitment to advancing medical science and improving treatment options for patients with cancer. His contributions to biotechnology are invaluable and continue to pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…